tbuckley/cabot-search huggingface dataset:
Responsive deep brain stimulation guided by ventral striatal electrophysiology of obsession durably ameliorates compulsion
Authors: Young-Hoon Nho, Camarin E. Rolle, Uros Topalovic, Rajat S. Shivacharan, Tricia N. Cunningham, Sonja Hiller, Daniel Batista, Austin Feng, Flint M. Espil, Ian H. Kratter, Mahendra T. Bhati, Marissa Kellogg, Ahmed M. Raslan, Nolan R. Williams, John Garnett, Bijan Pesaran, Desmond J. Oathes, Nanthia Suthana, Daniel A.N. Barbosa, Casey H. Halpern
Journal: Neuron (2023)

Treatment-resistant obsessive-compulsive disorder (OCD) occurs in approximately one-third of OCD patients. Obsessions may fluctuate over time but often occur or worsen in the presence of internal (emotional state and thoughts) and external (visual and tactile) triggering stimuli. Obsessive thoughts and related compulsive urges fluctuate (are episodic) and so may respond well to a time-locked brain stimulation strategy sensitive and responsive to these symptom fluctuations. Early evidence suggests that neural activity can be captured from ventral striatal regions implicated in OCD to guide such a closed-loop approach. Here, we report on a first-in-human application of responsive deep brain stimulation (rDBS) of the ventral striatum for a treatment-refractory OCD individual who also had comorbid epilepsy. Self-reported obsessive symptoms and provoked OCD-related distress correlated with ventral striatal electrophysiology. rDBS detected the time-domain area-based feature from invasive electroencephalography low-frequency oscillatory power fluctuations that triggered bursts of stimulation to ameliorate OCD symptoms in a closed-loop fashion. rDBS provided rapid, robust, and durable improvement in obsessions and compulsions. These results provide proof of concept for a personalized, physiologically guided DBS strategy for OCD.
1277P HRD status of patients with early stage non-small cell lung cancer
Authors: A. Klinakis, G. Christopoulou, A. Voutsina, G. Vatselas, K. Potaris, A. Chalari, K. Tsilingiri, I. Vamvakaris, T. Loupis, D. Vrachnos, G. Zachou, P. Constantoulakis, A. Kotsakis, V. Georgoulias
Journal: Annals of Oncology (2023)
1276P Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Authors: K. Yoh, Y. Zenke, S. Kitagawa, J. Samejima, T. Kasugai, H. Daga, K. Kunimasa, T. Kato, I. Nakachi, A. Osoegawa, S. Miyamoto, H. Izumi, T. Sakai, S. Umemura, E. Sugiyama, K. Murai, S. Matsumoto, M. Tsuboi, K. Goto
Journal: Annals of Oncology (2023)
1203P Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Authors: T. Satake, C. Morizane, N. Machida, Y. Honma, T. Okusaka, N. Boku, K. Kato, G. Ogawa, Y. Sano, H. Imaoka, S. Kobayashi, T. Terashima, M. Ikeda, N. Okano, K. Yamaguchi, T. Sato, N. Mizuno, Y. Kitagawa, M. Terashima, M. Ueno
Journal: Annals of Oncology (2023)
1267P Enhancing pulmonary nodule diagnosis: A combinatorial model of cfDNA methylation, plasma proteins and LDCT imaging
Authors: M. Yang, H-S. Yu, K-G. Wang, C-Y. Liang, J-H. Duan, H-L. Sun, H-X. Feng, B. Wang, B. Tong, J. Wang, Y. Wang, Y-Z. Zhou, X. Lu, H-X. Yang, W. Li, Q. He, Y. Zhang, Z. Su, R. Liu, J. Zhou
Journal: Annals of Oncology (2023)
1291O Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): A prospective multicentre, open-label, randomised, controlled trial
Authors: P. Vera, F. Le Tinier, P. Chaumet-Riffaud, E. Martin, N. Pourel, P. Boisselier, N. Salem, C. Le Pechoux, E. Giroux-Leprieur, S. Guillerm, C. Audigier Valette, D. Lerouge, C. Massabeau, P. Moisson, A. Larrouy, S. Hapdey, A. Langlais, E. Amour, G. Zalcman, P. Giraud, S. Thureau
Journal: Annals of Oncology (2023)
1198P Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings
Authors: J. Strosberg, G. Ulaner, D. Halperin, S.H. Mehr, D. Li, H.P. Soares, L.B. Anthony, S. Kotiah, H. Jacene, P.L. Kunz, D. Ferreira, J. Li, K. Ma, J. Rearden, S. Moran, T. Hope, S. Singh, M. Morris
Journal: Annals of Oncology (2023)
723O Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multi-cohort basket phase II trial (CABATEN/GETNE-T1914)
Authors: J. Capdevila Castillon, J. Molina-Cerrillo, M. Benavent Viñuales, R. Garcia-Carbonero, A. Teule, A. Custodio, P. Jimenez-Fonseca, C. López, C. Hierro, A. Carmona-Bayonas, J. Martínez-Trufero, M. Llanos, I. Sevilla, J. Hernando, T. Alonso-Gordoa, I. Gallego Jimenez, J. Gallego, B. Antón Pascual, E. Grande
Journal: Annals of Oncology (2023)
487P Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC)
Authors: J. Rand, C. Egelston, S. Chaurasiya, D. Yamauchi, J. Zhang, R. Pillai, J. Kessler, B. Modi, W.H. Meisen, L.O. Chong, A. Seiz, G. Selvaggi, N. Ede, N. Martinez, W. Borisuthirattana, S. Yost, J. Waisman, J. Mortimer, Y. Fong, Y. Yuan
Journal: Annals of Oncology (2023)
482P Precision imaging with human epidermal growth factor receptor 2-positron emission tomography (HER2-PET) for refined treatment selection in patients with HER2-low breast cancer
Authors: S. af Burén, R. Axelsson, E. Jussing, M. Karlsson, A. Blomgren, N. Brun, F.Y. Frejd, T.A. Tran, R. Altena
Journal: Annals of Oncology (2023)
481P Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials
Authors: M. Silveira Vilbert, D. Pinheiro Xavier, M. Goldner Cesca, L.V. Ravani, J. Chamadoira, C. Stecca, R. Costa, L. Cavalcante
Journal: Annals of Oncology (2023)
490P Metastatic breast cancer is associated with increased levels of soluble forms of TIM-3 and LAG-3 and decreased levels of soluble forms of GITR, GITR-L, CD27, CD28, CD40, CD86, ICOS, PD-L1, CTLA-4 and BTLA
Authors: T. Smit, B.L. Rapoport, H. Steel, L. Heyman, C-A. Benn, R. Anderson
Journal: Annals of Oncology (2023)
491P Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
Authors: N. Dobrić, N. Dandachi, E.V. Klocker, C. Suppan, R. Graf, S. Hasenleithner, P.J. Jost, E. Heitzer, M. Balic
Journal: Annals of Oncology (2023)
493P Identifying genomic changes in breast tumours that metastasise to the brain
Authors: I.C. Olivares, N. Ajaykumar, L.D. Birch, H. Allamsetty, K. Elango, D. Huen, T.P. Dawson, K. Ashton, C. Davis, M.D. Jenkinson, W. Wang, T.J. Warr, M.R. Morris
Journal: Annals of Oncology (2023)
483P Prognostic value of androgen receptor expression in patients with advanced triple-negative metastatic breast cancer treated with sacituzumab govitecan: A French multicentre retrospective study
Authors: M. Arnedos, B. Segier, N. Vincent, M. Robert, T. Grinda, T. Grellety, E. Deluche, J. Lehmann-Che, W. Jacot, M-F. Heymann, A. Lusque, M. Brunet, L. Teixeira, S. Guiu
Journal: Annals of Oncology (2023)
484P Multi-platform characterization of HER2 expression in triple-negative breast cancer
Authors: A.C. Garrido-Castro, J. Gomez Tejeda Zanudo, J. Navarro, E.T. Richardson, A. Frangieh, A.M. Barkell, A. Mohammed-Abreu, M.E. Hughes, B. Binboga Kurt, T.A. King, E.A. Mittendorf, D. Carroll, S.M. Tolaney, E.C. De Bruin, N.U. Lin
Journal: Annals of Oncology (2023)
485P A novel approach to identify subpopulation of CTCs with metastatic potential using sc-RNA-seq
Authors: E. Grigoryeva, L. Tashireva, V.V. Alifanov, M. Zavyalova, M. Menyailo, E.V. Denisov, N.O. Popova, N. Cherdyntseva, V. Perelmuter
Journal: Annals of Oncology (2023)
443P Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer
Authors: C. Karacin, F. Aslan, A. Dumludag, A. Alkan, M. Türker, K. Bir Yucel, E. Mutlu, S. Kahraman, M. Ayhan, O.U. Unal, A. Türkel, Y. Iriagac, E. Aydin, Y. Ergün, N. Karadurmus, O. Ates, O. Yazici, S. Paydas, I. Erturk
Journal: Annals of Oncology (2023)
449P Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
Authors: C. von Arx, A. Calabrese, C. Martinelli, V. Di Lauro, V. Grimaldi, M. Pensabene, R. Caputo, I. Cerillo, D. Cianniello, G. Buono, A. Verrazzo, C. Pacilio, F. Di Rella, F. Nuzzo, M. De Laurentiis
Journal: Annals of Oncology (2023)
431P Distribution and prognostic role of HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2- metastatic breast cancer (MBC) patients (pts)
Authors: E. Nicolo, L. Munoz-Arcos, P. D'Amico, Y. Zhang, L. Gerratana, M. Serafini, L. Pontolillo, K. Strickland, M. Manai, A.A. Davis, J. Donahue, H. Liu, W.J. Gradishar, A.N. Shah, G. Curigliano, C. Reduzzi, M. Cristofanilli
Journal: Annals of Oncology (2023)
444P Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple-negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial
Authors: H. Li, D. Zhou, Z. Yv, Y. Liao, J. Huang, S. Sun, F. Zheng, B. Li, S. Fang, L. Qiang, None G. ren, X. Wang, B. Zhang, B. Fan, X. Zhao, W. Li, Z. Wang, H. Fu, X. Sun, Z. Shi
Journal: Annals of Oncology (2023)
442P Menopausal status may derive in different second-line treatment benefits in breast cancer patients that experienced disease progression with CDK4/6 inhibitors (SUMA-001)
Authors: F.D. Waisberg, P. Mando, C. Almada, N. Kassis, A.C. Mainella, L. Cermignani, M.C. Riggi, M. Winocur, A. Guercovich, N.C. Ayala, C. Micheri, A.C. Ituarte, L. Gonzalez Mattos, P. Lludgar, M.L. Casalnuovo, M.A. Lutteral, S. Cinquini, G. Gomez-Abuin
Journal: Annals of Oncology (2023)
437P Improving safety and convenience for breast cancer patients receiving CDK 4/6 inhibitor treatment via a telemedicine app
Authors: B. Mrinakova, J. Simko, J. Eggova, M. Hancinova, B. Vertakova Krakovska, S. Putekova, J. Homolova, D. Ondrus, F. Lehocki
Journal: Annals of Oncology (2023)
432P Ki67 and progesterone receptor status could be predict sensitivity to cyclin-dependent kinase inhibitor
Authors: L. Navarro Berlanga, B. Teso, P. Flores Paco, J. De la Haba Rodriguez, A. Armenta, F. Mora, B. Rodriguez Alonso, C. Morales Estevez, I. Porras Quintela, P. Sanchez Mauriño, E. Aranda Aguilar
Journal: Annals of Oncology (2023)
441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study
Authors: A. Woeckel, C. Brucker, T. Decker, P. Fasching, T. Göhler, C. Jackisch, J. Janssen, A. Koehler, K. Luedtke-Heckenkamp, None D. Lüftner, M. Van Mackelenbergh, F. Marmé, A. Nusch, B. Rautenberg, T. Reimer, R. Weide, P. Wimberger, S. Maslanka Figueroa, C. Roos, M. Schmidt
Journal: Annals of Oncology (2023)
429P The impact of HER2 status on the efficacy of CDK 4/6 inhibitors: A multicenter study
Authors: H.C. Yildirim, M. Büyükkör, B. Sahin, K. Bir Yucel, B. Dursun, E. Chalabiyev, F. Tay, S. Sim Yildirim, G. Kavgacı, F. Yılmaz, A. Turgut, B. Köksal, D.C. Guven, Y. Urun, O. Yazici, E. Gokmen, B.O. Oksuzoglu, S. Aksoy
Journal: Annals of Oncology (2023)
308P Regression-based deep-learning predicts breast cancer recurrence risk score from pathology slides
Authors: O.S.M. El Nahhas, C.M.L. Loeffler, A. Marra, Z. Carrero, F. Pareja, H. Wen, B. Weigelt, P. Selenica, S. Chandarlapaty, J.S. Reis-Filho, J.N. Kather
Journal: Annals of Oncology (2023)
323P Macrophage population analysis of the breast cancer microenvironment within the context of seroma formation after mastectomy (SerMa pilot study)
Authors: F. Schneider, M. Köpke, C. Kuhn, M. Wild, M. Schneider, C. Dannecker, L.C. Hinske, U. Jeschke, N. Ditsch
Journal: Annals of Oncology (2023)
320P Clinical and pathological characteristics of breast cancers switching from early luminal-like to metastatic triple-negative phenotype
Authors: M. Ivanova, A. Marra, S. Morganti, K. Venetis, E. Sajjadi, L. Ascione, B. Taurelli Salimbeni, P. Zagami, P.P.M. Berton Giachetti, G. Curigliano, N. Fusco, C. Criscitiello
Journal: Annals of Oncology (2023)
315P Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on perceptions on testing
Authors: S.L. Powell, M. Artigas, I. Borovova, P. Gadiya, A. Hsu, R. Kaur, L. Kidd, D. Rosenfeld, M.M. Saeed, E. Scarelli, M. Wahib
Journal: Annals of Oncology (2023)
324P Nodal underestimation rate in early-stage ER+/HER2- breast cancer patients with limited positive sentinel lymph nodes in the era of precise medicine: A real-world multicenter analysis from 40 institutions in China
Authors: Y. Zong, Y. Lu, Y. Tong, X. Fei, Y. Zhu, Z. Wang, X. Zhang, Y. Zhu, J. Huang, J. Hong, S. Zhu, W. Gao, X. Chen, O. Huang, J. He, W. Chen, Y. Li, K. Shen, J. Wu
Journal: Annals of Oncology (2023)
305P Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
Authors: S. Kang, S.H. Lee, H.J. Lee, H. Jeong, J-H. Jeong, J.E. Kim, J-H. Ahn, K.H. Jung, H.H. Kim, S. Lee, J. Lee, S-B. Kim
Journal: Annals of Oncology (2023)
333P Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)
Authors: M.A. Hennessy, A. Cimino-Mathews, J. Carter, J. Kachergus, Y. Ma, J. Leal, L. Solnes, V. Abramson, L.A. Carey, M. Rimawi, J. Specht, A.M. Storniolo, C. Vaklavas, A.C. Wolff, R. Wahl, E.A. Perez, C-Y. Huang, V. Stearns, A. Thompson, R.M. Connolly
Journal: Annals of Oncology (2023)
312P Prediction model of breast cancer patient’s neoadjuvant treatment outcome using breast cancer organoids cultured from core needle biopsies
Authors: D.W. Lee, G.Y. Kim, K.H. Park, B.J. Chae, J.E. Lee, S.W. Kim, S.Y. Jang, J.Y. Choi, J.M. Ryu, S.K. Lee, J.H. Yu, S.J. Nam, B. Ku
Journal: Annals of Oncology (2023)
321P Non-BRCA variants in hereditary breast and ovarian cancer patients in the northern Mexico population
Authors: D. Aguilar, M.D.L. Garza Rodriguez, D.C. Pérez-Ibave, C.M. Villarreal Garza, O. Vidal-Gutierrez, C.H. Burciaga Flores
Journal: Annals of Oncology (2023)
307P Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline
Authors: X. Zhu, J. Bayani, M. Dewan, H. Tovey, L. Kilburn, K. Taylor, J. Banerji, C. Toms, A. Sadanandam, P.J. Barrett-Lee, J. Bliss, D.A. Cameron, J.M.S. Bartlett, M.C.U. Cheang
Journal: Annals of Oncology (2023)
317P Awareness of genomic testing among patients with breast cancer in Europe
Authors: A. Cardone, D. Bell, C.B. Biurrun, F. Cardoso, L.D. Csaba, L. Guéroult-Accolas, M.P. Lux, A. Ramírez Piris, I. Rubio, R. Simcock, R. D’Antona Fidanzia
Journal: Annals of Oncology (2023)
309P Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up
Authors: I. Zerdes, A. Matikas, A. Mezheyeuski, B. Acs, H. Johansson, G. Manikis, C. Boyaci, C.E. Boman, C. Poncet, M. Ignatiadis, Y. Bai, D. Rimm, G. MacGrogan, D.A. Cameron, J. Bergh, H. Bonnefoi, T. Foukakis
Journal: Annals of Oncology (2023)
318P Evaluation of novel diagnostic kits using the semi-dry dot-blot method combined for detecting metastases in sentinel lymph nodes of patients with breast cancer: A multi-center prospective study
Authors: R. Otsubo, M. Matsumoto, E. Inamasu, A. Tanaka, S. Kuba, M. Morita, F. Kaseida, S. Maeda, M. Nakashima, H. Ikari, S. Ohno, H. Takei, S. Eguchi, T. Nagayasu
Journal: Annals of Oncology (2023)
403P Breast cancer specific survival (BCSS) in HR+/HER2- metastatic breast cancer (mBC) from 2010 to 2019
Authors: A.M. Brufsky, M. Kwan, R. Sandin, S. Karanth, A. Cha-Silva, D. Makari, S. Stergiopoulos, R. Goyal
Journal: Annals of Oncology (2023)
388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
Authors: J. Tsurutani, W. Jacot, T. Yamashita, F. Riaz, R. Yerushalmi, S-A. Im, N. Niikura, U. Halser-Strub, J. Cortés, A-K. Wennstig, Y. Chae, X. Wang, W. Li, H. Simon, G. Masci, E. Tamburini, C. Orbegoso Aguilar, K. Tecson, L. Yung, S. Modi
Journal: Annals of Oncology (2023)
395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Authors: K.H. Jung, S.J. Luen, M. Oliveira, J. Sohn, S-A. Im, S. Wander, S.A. Hurvitz, A. Sonnenblick, V. Breton, A. Collier, S. Deb, H. Ngo, R. Schwab, C. Shemesh, J. Zhu, C. Hernando Melia
Journal: Annals of Oncology (2023)
400P The impact of CDK4/6 inhibitors on bone health: An Italian real-world experience
Authors: R. Scafetta, F. Pantano, M. Donato, C. Fiore, S. Foderaro, A. Guarino, C. Gullotta, L. Sisca, V. Ricozzi, U.F.F. De Giorgi, D. De Lisi, M.A. Fabbri, A. Irelli, I. Portarena, E. Tiberi, A. Verrazzo, F. Villa, G. Tonini, B. Vincenzi, D. Santini
Journal: Annals of Oncology (2023)
405P E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2− BC): Results from a phase I study dose-expansion part
Authors: K. Yonemori, Y. Miyoshi, H. Yasojima, J. Watanabe, T. Takano, A. Shimomura, E. Tokunaga, T. Mukohara, Y. Naoi, S. Okumura, T. Suzuki, Y. Otake, D. Matsuoka, T. Takase, T. Semba, H. Ishiguro
Journal: Annals of Oncology (2023)
398P A phase Ib/II study of IN10018/FAKi in combination with pegylated liposomal doxorubicin (PLD) and toripalimab in metastatic triple-negative breast cancer (TNBC): IN10018-010
Authors: X. Hu, Q. Ouyang, M. yan, C. Wenyan, S. Cang, Y. Huang, C. Tian, Z. Tao, S. Xie, Y. Zhu, Z. Wang
Journal: Annals of Oncology (2023)
389P Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)
Authors: J. Cortés, F. Marmé, P. Schmid, H.S. Rugo, S.M. Tolaney, W. Verret, T. Valdez, Y. Huo, A. Bardia
Journal: Annals of Oncology (2023)
387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer
Authors: T. Pascual, E. Segui Solis, R. Olivera-Salguero, J.M. Cejalvo, M. Oliveira, P. Tolosa Ortega, M.J. Vidal Losada, M. Malumbres, J. Gavilá-Gregori, C. Saura Manich, S. Pernas Simon, M. Margeli Vila, E.M. Ciruelos, E. Galve-Calvo, P. Galván, E. Sanfeliu Torres, R. Olmos, M. Forns, A. Casas Fernandez Tejerina, A. Prat
Journal: Annals of Oncology (2023)
399P Results from a first-in-human phase Ia/b study of LX-039, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal patients with ER+, HER2- advanced breast cancer (ABC)
Authors: W. Shen, X. Hu, J. Zhang, J. Cao, H. Yao, X. Wang, Y. Chen, Y. Du, Z. Tao, L. Wang, C. Hu, C. Li
Journal: Annals of Oncology (2023)
401P Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer with brain metastasis (UTOBIA-BM): A prospective, single-arm, phase II trial
Authors: Y. Shi, P. Wang, Y. Zhu, X. Wang, S. Li, B. Zhang, Z. Yuan, J. You, B. Zhang, Y. Zheng
Journal: Annals of Oncology (2023)
394P CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
Authors: F. Pantano, R. Scafetta, G. Curigliano, C. Criscitiello, A. Botticelli, R. Caputo, G. D'Auria, O. Garrone, S. Gori, I. Meattini, M. Minelli, M. Piras, L. Rossi, L.S. Stucci, B. Tagliaferri, A. Toss, C. Vernieri, P. Vici, G. Tonini, D. Santini
Journal: Annals of Oncology (2023)
392P The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
Authors: S. Lammers, H. Thurisch, I.J.H. Vriens, M. Meegdes, S.M.E. Engelen, F.L.G. Erdkamp, M. Dercksen, B. Vriens, K. Aaldering, M. Pepels, L.V.D. Winkel, N. Peters, J. Tol, J.B. Heijns, A. van de Wouw, N. Teeuwen, S. Geurts, V. Tjan-Heijnen
Journal: Annals of Oncology (2023)
390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial
Authors: E.P. Hamilton, H. Han, A. Schott, A. Tan, R. Nanda, D. Juric, N. Hunter, P. Munster, B. Fang, G. Zahrah, J. Ranciato, R. Gedrich, E. Zhi, Y. Zhang, W. Tan, C. Mather, J. Perkins, S. Anderson, S.A. Hurvitz
Journal: Annals of Oncology (2023)
404P A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer
Authors: J. Wang, Q.Y. Zhang, T. Sun, H. Li, Y. Cheng, H. Li, Z. Tong, J. Wang, W. Li, X. Wu, Y. Teng, J. Cheng, Z. Chen, Z. Zhu, C. Shih, L. Wang, M. Liu, H. Xu, X. Duan, B. Xu
Journal: Annals of Oncology (2023)
393P Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
Authors: K. Kalinsky, L. Spring, C. Yam, I. Ntalla, B. Stwalley, N. Sjekloca, C. Lai, A. Kaushiva, A.J. Taylor, R. Nanda
Journal: Annals of Oncology (2023)
396P Real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer (mTNBC) in the United States (US)
Authors: K. Punie, A. Kurian, I. Ntalla, D.H. Huynh, N. Sadetsky, A. Estrin, E. Dabrowski, N. Sjekloca, C. Lai, S.A. Hurvitz
Journal: Annals of Oncology (2023)
402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study
Authors: H.A. Azim, N.S. El Saghir, Y.S. Yap, Y. Eralp, S-A. Im, M.S. Sandhu, H. Abdel-Razeq, S. Gupta, E. Artamonova, J. Rihani, T. Delgar Alfaro, J. Wu, H. Hu, M. Gao, Y-S. Lu
Journal: Annals of Oncology (2023)
365P Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study
Authors: B. Wang, C. Zhong, Z. Liao, H. Wang, X. Cai, Y. Zhang, J. Wang, T. Wang, H. Yao
Journal: Annals of Oncology (2023)
363P High adipocytokines and IL-18bp serum levels are associated with lower objective response rate after neoadjuvant treatment in breast cancer patients with metabolic syndrome
Authors: L. Mont'Alverne Arruda, G. de Lima Freitas, L. Guimarães Franco da Silva, J. Sales Bonfim da Silva, I. de Fátima Vieira Camelo Maia, A. Gomes Cajado, C. Choquenaira Quispe, B.G. Alves, L.D.C.A. Guimaraes, A.B. Lustosa, I. Rocha, A.B.T. Filgueiras, L.F. Oliveira Torres, J.P. Holanda Soares, F. Bitencourt, P. Goberlanio, M.D.P.S.S. Cunha, R.C. Pereira Lima-Jr, D.V. Tenazoa Wong
Journal: Annals of Oncology (2023)
360P Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study
Authors: Y. Chai, M. Jiang, J. Liu, M. He, X. Wang, Y. Wang, X. Yang, J. Wang, B. Xu, Q. Li
Journal: Annals of Oncology (2023)
372P Prevalence of BRCA1 and BRCA2 mutation among Indian breast cancer patients: A multicentre cross-sectional study
Authors: S. Nag, D. Arya, S.J. Rajappa, N.K. Warrier, A. Kapoor, J. Ghosh, A. Batra, S.S. Panda, S. Kate, G. Prakash, C. Goswami, S.V. Almel, S. Aggarwal, R. Kodagali, K. Bhatt, S. Gupta
Journal: Annals of Oncology (2023)